# Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

> **NCT05347979** · PHASE1 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Cushing Syndrome
- Neoplasms

## Interventions

- **DRUG:** Dabigatran Etexilate
- **DRUG:** Relacorilant

## Key facts

- **NCT ID:** NCT05347979
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-25
- **Primary completion:** 2022-07-19
- **Final completion:** 2022-07-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05347979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05347979, "Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05347979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*